Who are Test: Metronidazole Gel 1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metronidazole (Metrogel), Metronidazole Suppositories, Metronidazole Tablet, Amoxicillin, Metronidazole, Metronidazole 400 (7 days), Metronidazole (BQ10).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/test-metronidazole-gel-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Test: Metronidazole Gel 1% — Competitive Intelligence Brief

Test: Metronidazole Gel 1% (Test: Metronidazole Gel 1%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: nitroimidazole antibiotic. Area: Dermatology.

phase 3 nitroimidazole antibiotic Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Test: Metronidazole Gel 1% (Test: Metronidazole Gel 1%) — bioRASI, LLC. Metronidazole gel 1% works by killing bacteria and other microorganisms that cause infections.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Test: Metronidazole Gel 1% TARGET	Test: Metronidazole Gel 1%	bioRASI, LLC	phase 3	nitroimidazole antibiotic
Metronidazole (Metrogel)	Metronidazole (Metrogel)	LEO Pharma	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole Suppositories	Metronidazole Suppositories	Dongfang Hospital Beijing University of Chinese Medicine	marketed	Nitroimidazole antibiotic	Bacterial/protozoal DNA
Metronidazole Tablet	Metronidazole Tablet	Appili Therapeutics Inc.	marketed	Nitroimidazole antibiotic	Bacterial and parasitic DNA
Amoxicillin, Metronidazole	Amoxicillin, Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Penicillin-binding proteins (amoxicillin); anaerobic DNA (metronidazole)
Metronidazole 400 (7 days)	Metronidazole 400 (7 days)	University of Guarulhos	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA
Metronidazole (BQ10)	Metronidazole (BQ10)	National Taiwan University Hospital	marketed	Nitroimidazole antibiotic	Bacterial/parasitic DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (nitroimidazole antibiotic class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
bioRASI, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Test: Metronidazole Gel 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/test-metronidazole-gel-1. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab